First major licensing deal for an exosome therapeutics in Korea

Brexogen, a leading biotechnology company specialising in exosome-based therapeutics, has announced a technology transfe...

February 20, 2025 | Thursday | News
Japan's NEC invests in Aetion, US-based provider of healthcare analytics platforms

NEC Orchestrating Future Fund, an ecosystem-based corporate venture capital (CVC) fund, has invested in Aetion, Inc., a ...

February 19, 2025 | Wednesday | News
Saudi German Health partners with BD to introduce rapid diagnostic solutions

Saudi German Health (SGH) has signed a Memorandum of Understanding (MoU) with Becton, Dickinson and Company (BD), a...

February 19, 2025 | Wednesday | News
SingHealth and Philips join hands to advance digital-first healthcare with AI integration

Royal Philips, a global leader in health technology, and SingHealth, Singapore's largest public healthcare clu...

February 19, 2025 | Wednesday | News
Novotech inks MoU with Wonju Severance Christian Hospital to drive clinical research excellence in Korea

Novotech, a global full-service clinical Contract Research Organisation (CRO) that partners with biotech and small to mi...

February 19, 2025 | Wednesday | News
HMRI partners with Novartis Australia to supercharge heart health

The Hunter Medical Research Institute (HMRI) has announced a new partnership with Novartis Australia, formalised through...

February 19, 2025 | Wednesday | News
Japan builds machine learning model to predict amyloid beta accumulation in brain

Oita University and Eisai Co., in Japan, have announced the development of a machine learning model to predict amyloid b...

February 17, 2025 | Monday | News
Teva Reports $4.2B Q4 2024 Revenue as Specialty Medicines and Biosimilars Drive Growth

Teva Pharmaceuticals' Q4 2024 results reflect both the challenges and successes of the company as it continues its "Pivo...

February 17, 2025 | Monday | Company results
Takeda Reports Strong Q4 2024 Performance with 9.8% Revenue Growth, Driven by Oncology and Plasma-Derived Therapies

Takeda Pharmaceuticals has released its financial report for the fourth quarter of 2024, showcasing strong financial per...

February 17, 2025 | Monday | Company results
SK Bioscience Reports 73% Revenue Growth in Q4 2024, Driven by IDT Biologika Acquisition and Vaccine Expansionv

SK Bioscience reported strong revenue growth in Q4 2024, primarily driven by the consolidation of IDT Biologika, expansi...

February 17, 2025 | Monday | Company results
Pfizer Reports Strong Q4 2024 with $17.8B Revenue, Driven by Oncology and Cardiovascular Growth

Pfizer reported a strong fourth quarter (Q4) of 2024, achieving $17.8 billion in total revenues, reflecting a 21% year-o...

February 17, 2025 | Monday | Company results
Novartis Reports Strong Q4 2024 with 16% Sales Growth, Driven by Cardiovascular, Oncology, and Immunology Therapies

Novartis delivered a strong Q4 2024 performance, with net sales growing by 16% year-over-year (YoY) at constant currency...

February 17, 2025 | Monday | Company results
Moderna Reports $966M Q4 2024 Revenue Amid COVID-19 Vaccine Decline, Focuses on mRNA Pipeline Expansion

Financial Performance Overview Moderna reported Q4 2024 revenue of $966 million, marking a 66% decline year-over-year (...

February 17, 2025 | Monday | Company results
GSK Reports Strong Q4 2024 Growth in Specialty Medicines and HIV, Offsetting Vaccine Declines

GSK delivered a strong performance in Q4 2024, with total sales reaching £8.12 billion, reflecting a 4% year-over-...

February 17, 2025 | Monday | Company results
Eli Lilly Reports Record Q4 2024 Revenue of $13.53B, Fueled by Mounjaro, Zepbound, and Oncology Growth

Eli Lilly & Co. reported a strong financial performance in Q4 2024, with substantial revenue growth driven by its bl...

February 17, 2025 | Monday | Company results
Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges

Key Financial Highlights Biogen Inc. reported its fourth-quarter (Q4) and full-year 2024 results on February 12, 2025. ...

February 17, 2025 | Monday | Company results
AstraZeneca Reports Strong Q4 2024 Growth with $14.89 Billion Revenue, Driven by Oncology and Innovative Therapies

  AstraZeneca delivered a strong performance in Q4 2024, with Total Revenue reaching $14.89 billion, marking a 24%...

February 17, 2025 | Monday | Company results
Korea's Hanmi Pharma introduces new automated vial dispensing solution in Canada and US

South Korea-based Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team is making significant strides ...

February 15, 2025 | Saturday | News